Study of Abatacept in the Treatment of Hospitalized COVID-19 Participants With Respiratory Compromise

Summary

The purpose of this study is to evaluate the efficacy and safety of intravenous abatacept administered to hospitalized COVID-19 participants with respiratory compromise.

Timeline

Start

2020-10-14

Primary completion

2021-08-12

Completion

2021-09-13

Outcome

Missed primary endpoint

Stopped (Enrollment): “Slow accrual”

registry analysis (superiority test); Abatacept vs Placebo; p = 0.9297; Odds Ratio (OR) 1.07 (95% CI 0.26 to 4.49); NCT04472494 ↗

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Abatacept	Other / unclassified	—	Intravenous

Indications